Shares of Chemours Company (The) (NYSE:CC) have received an average rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $56.43.

Several research firms recently weighed in on CC. UBS AG restated a “sell” rating and issued a $36.00 price objective (up from $35.00) on shares of Chemours Company (The) in a report on Wednesday, June 14th. BidaskClub downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research upgraded shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $61.00 target price for the company in a report on Tuesday, October 3rd. Argus reiterated a “buy” rating and issued a $55.00 target price (up from $50.00) on shares of Chemours Company (The) in a report on Thursday, August 10th. Finally, Jefferies Group LLC boosted their target price on shares of Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/12/chemours-company-the-cc-given-average-rating-of-buy-by-brokerages.html.

Shares of Chemours Company (NYSE CC) traded up 0.58% on Thursday, reaching $55.44. 894,736 shares of the company’s stock traded hands. Chemours Company has a 12-month low of $14.41 and a 12-month high of $55.55. The firm has a market cap of $10.25 billion, a P/E ratio of 36.28 and a beta of 3.59. The stock has a 50-day moving average of $51.91 and a 200 day moving average of $51.91.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.02. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.27 earnings per share. On average, equities research analysts expect that Chemours Company will post $3.54 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were issued a dividend of $0.03 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $0.12 annualized dividend and a dividend yield of 0.22%. Chemours Company (The)’s dividend payout ratio (DPR) is currently 8.11%.

In other news, VP Amy Trojanowski sold 2,500 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David C. Shelton sold 19,000 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $53.68, for a total transaction of $1,019,920.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 57,837 shares of company stock worth $2,885,523. Corporate insiders own 1.14% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Park National Corp OH purchased a new stake in Chemours Company (The) in the third quarter valued at approximately $231,000. Navellier & Associates Inc purchased a new stake in Chemours Company (The) in the second quarter valued at approximately $2,632,000. Archford Capital Strategies LLC purchased a new stake in Chemours Company (The) in the second quarter valued at approximately $1,178,000. Cookson Peirce & Co. Inc. purchased a new stake in Chemours Company (The) in the second quarter valued at approximately $2,703,000. Finally, Public Employees Retirement System of Ohio boosted its position in Chemours Company (The) by 306.4% in the second quarter. Public Employees Retirement System of Ohio now owns 98,590 shares of the specialty chemicals company’s stock valued at $3,739,000 after buying an additional 74,329 shares during the last quarter. Hedge funds and other institutional investors own 72.90% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.